Saxagliptin Cardiotoxicity in Chronic Heart Failure: The Role of DPP4 in the Regulation of Neuropeptide Tone

Dipeptidyl-peptidase-4 (DPP4) inhibitors are novel medicines for diabetes. The SAVOR-TIMI-53 clinical trial revealed increased heart-failure-associated hospitalization in saxagliptin-treated patients. Although this side effect could limit therapeutic use, the mechanism of this potential cardiotoxici...

詳細記述

書誌詳細

主要な著者:	Imre Vörös, Zsófia Onódi, Viktória Éva Tóth, Tamás G. Gergely, Éva Sághy, Anikó Görbe, Ágnes Kemény, Przemyslaw Leszek, Zsuzsanna Helyes, Péter Ferdinandy, Zoltán V. Varga
フォーマット:	Artigo
言語:	Inglês
出版事項:	MDPI AG 2022-07-01
シリーズ:	Biomedicines
主題:	saxagliptin neuropeptide Y substance P neuropeptides diabetes heart failure
オンライン･アクセス:	https://www.mdpi.com/2227-9059/10/7/1573
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!